Ophthalmology Department of the Medical Center Institute of Peptide Bio Regulation.
For the first time in the world medical and ophthalmological practice an unprecedented technology for restoration and treatment of retinal functions in case of different pathologies (including macular degeneration, retinitis pigmentosa, diabetic retinopathy, thermal injuries, etc.) has been discovered.
The technology is based on peptide bioregulators, isolated from animal organs and tissues, such as retina, vessels, brain, thymus, epiphysis or their synthesized analogues. In case of introduction into the organism, peptides become induktors of synthesis of the specific proteins, capable of restoring tissues, damaged by a disease or with ageing.
The efficiency of the conducted treatment course was evaluated according to the indices of visual acuity, electrophysiological test, eyeball image and subjective state of each patient. Improved visual functions were registered in 95% of the patients, which is absolutely unique. Nowadays in the world of medicine there are no methods of treatment for retinal diseases whose efficiency is comparable to that of the treatment with peptide bioregulators.
At our Medical Center you can undergo the full course of the necessary ophthalmological examinations:
Consultation and complex examination
Eidoptometry with correction
Field of vision analysis
Fundoscopy with photorecording
Diagnostics of functional status of the lacrimal apparatus and lacrimal passages
Electrophysiological examination of retina
PRIORITY AREA OF CLINICAL ADMINISTRATION OF THE PEPTIDE BIOREGULATORS IN OPHTHALMOLOGY:
Macular degeneration: dry and wet forms
Recurrent post traumatic and post-inflammatory retinal degenerations
Tapetoretinal eye degeneration
TREATMENT OF RETINAL PATHOLOGIES WITH PEPTIDE BIOREGULATORS
Retinitis pigmentosa – is one of the most severe and frequent hereditary retinal diseases. At the Medical Center of the Institute we’d treated patients from different countries that failed to get any help in any other medical institutions and came to us after several years of desperate attempts to improve or stabilize their vision functions.
We should emphasize that right after the first treatment course they reported increased visual acuity, significant widening of the fields of vision, improved scotopic (twilight) vision. With every reason we may say that there are no examples of such positive results observed after the treatment of this pathology in the world. In case a patient regularly undergoes courses of peptide bioregulators we reveal no negative dynamics of this severe pathology at all.
Treatment of Retinitis Pigmentosa with peptide bioregulators
Age-related macular degeneration
Pathogenic pathway is influenced by oxidativ stress, immune inflammations, lipidosis and hereditary background. It may also be related with smoking an elevated blood pressure.
In the developed countries of the world age-related macular degeneration is a leading cause of the blindness in patients aged 50+ . Thus the importance of regular preventive examination is extremely crucial. Such examinations enable to diagnose the degeneration on early stages and take necessary remedial measures accordingly.
Recently at the Institute of Bioregulation we have gained quite wide experience of treatment of such patients. We manage not only to stop the development of the pathologic process but in many cases also to restore lost functions. Peptide bioregulators are effective in the treatment of both wet and dry macular degenerations. The effect is preserved in case of long-term treatment. Regular application of peptide bioregulators allows to enhance the achieved results.
PRIORITY INDICATIONS FOR PEPTIDE BIOREGULATORS
Prevention of premature ageing
Correction of pathologic alterations.
Improvement of intellectual and physical working capacity.
Prevention and treatment of age-related pathology
Cardio-vascular function disorders.
Metabolic and hormonal disorders.
Treatment of eye diseases
Hereditary tapetoretinal degeneration.
Central and peripheral tapetoretinal abiotrophies with prevalent changes in pigmented epithelium.
Secondary posttraumatic and post-inflammatory central retinal degeneration.
Pigmented retinal degeneration of various etiologies.
Initial stage of cataract of various etiologies.
Neurological diseases treatment
Craniocerebral trauma at the stage of rehabilitation and residual period.
Cerebral blood circulation disorders at the stage of rehabilitation and residual period.
Degeneration of vertebral column.
Correction of hormonal shifts
Dysfunctional climacteric uterine hemorrhages caused by anovulatory process involving
Prevention and treatment of urogenital disease
Benign hyperplasia of the prostate.
Traumas of the urinary bladder, urethra and prostate.
Prevention and treatment of age-related skin alterations (gerontocosmetology)
Dry and thin skin.
Teleangiectasia, spider angioma.